USPTO serial 79289202
XL-PROTEIN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 18, 2022
- Examiner
- VAGHANI, MAYUR C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with XL-PROTEIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Anthony G. Craig
Anthony G. Craig Sci-Law Strategies, PCPO Box 1729Solana Beach, CA 92075UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical and biochemical preparations for use in biochemical research laboratories, in chemical research laboratories, in biotechnological research laboratories or in pharmaceutical research laboratories, other than for medical and veterinary use, as well as for industrial and scientific use | ACTIVE | — |
| 005 | Pharmaceutical, medical and veterinary preparations for the treatment of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases or bone diseases; Pharmaceutical preparations for the treatment of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, or bone diseases and diagnostic reagents for use in medicine and dentistry; Test kit reagents for use in medicine and dentistry; Chemical, biochemical and biotechnological preparations for medical and diagnostic use, namely reagents for medical purposes and solvents for sample preparation, modification and manipulation of cells as well as for use in methods for labeling, separation, isolation, purification, multiplication and analysis of biopolymers, especially nucleic acids, proteins, macromolecules and biologically active substances for medical diagnostic use; Drugs for preventive, curative and palliative purposes, namely for the treatment of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, or bone diseases; Diagnostic medical biomarkers, especially for preventive, diagnostic, prognostic or predictive use; Medical preparations, namely, kits for use in medical laboratories, especially for preventive, diagnostic, prognostic or predictive use composed of proteinaceous reagents for medical purposes; Biomolecules for medical use, namely, for binding of active agents in the field of treatment of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, or bone diseases; Medical preparations for use in medical diagnostic for the treatment of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, or bone diseases; Chemical and biological preparations for medical and diagnostic purposes for the treatment of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, or bone diseases | ACTIVE | — |
| 042 | Scientific and technological services and research, namely, scientific research, analysis, and testing, and research all in the field of chemistry, genetics, biology, biotechnology and biochemistry; Medical or scientific laboratory services, namely, testing services in the field of DNA, RNA as well as protein expression, detection and analysis and design relating thereto, especially in the field of chemistry, genetics, biology, biotechnology and biochemistry; Services of a chemical and biochemical scientific or medical laboratory; Technological services, namely, technical processing in the nature of product development and technical scientific analysis of biomaterials and medically relevant data especially for scientific and industrial research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by XL-protein GmbH
- Other trademarks owned by XL-protein GmbH
- Other trademarks owned by XL-protein GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named XL-PROTEIN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 18, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 27, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 27, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 18, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 18, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 1, 2022 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 15, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 15, 2021 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 8, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Nov 2, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 2, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 13, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 13, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 13, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 29, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 28, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 28, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 28, 2021 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 30, 2021 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 30, 2021 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 30, 2021 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 10, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 9, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 9, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 4, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 14, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 14, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 18, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 17, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 14, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 14, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 10, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 9, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |